Tag

Stock Crash

All articles tagged with #stock crash

business1 month ago•4 min saved

Intel Stock Slumps on Weak Forecast and Supply Disruptions

Intel's shares tumbled about 17% after a subpar sales and profit forecast and warnings of supply disruptions. Q4 revenue fell 4% YoY to $13.7B, with weakness in the Client Computing Group offsetting gains in Data Center & AI. The firm posted adjusted EPS of $0.15, beating estimates, but guided Q1 revenue of $11.7–$12.7B and said it will likely break even on adjusted EPS. Executives cited supply shortfalls and ongoing challenges winning foundry customers from rivals like TSMC, fueling investor concern about Intel's growth outlook.

via The Motley Fool|

#business #earnings-forecast #intc

business2 months ago•1 min saved

Oracle Shares Drop Amid Funding Uncertainty for Michigan Data Center

Oracle's shares dropped about 5% after Blue Owl Capital withdrew from funding a $10 billion AI data center project, raising concerns about the company's ability to finance large-scale AI infrastructure amid broader tech sector volatility and investor scrutiny.

via Yahoo Finance|

#ai-infrastructure #blue-owl-capital #business

business2 months ago•2 min saved

Quantum Computing Stocks to Watch: Opportunities and Risks Ahead

The article predicts that shares of Rigetti Computing and D-Wave Quantum, which have surged dramatically since 2023, will crash in 2026 due to the bursting of the quantum computing bubble, as large-scale, fault-tolerant quantum computers are still at least a decade away and the market for quantum computing remains relatively small compared to AI.

via Yahoo Finance|

#bubble-burst #business #d-wave-quantum

business4 months ago•1 min saved

uniQure's Huntington's Gene Therapy Faces FDA Setback

Uniqure's stock dropped 59% after the FDA provided confusing and unexpected feedback regarding its Huntington's disease gene therapy, AMT-130, casting doubt on the company's plans for approval and indicating a key shift from previous communications.

via Investor's Business Daily|

#business #fda #gene-therapy

business5 months ago•1 min saved

MoonLake's Stock Plummets 89% Amid Autoimmune Drug Trial Failures

MoonLake Immunotherapeutics' stock plummeted over 88% after its skin disease treatment, sonelokimab, showed only mixed results in clinical trials for hidradenitis suppurativa, with only one of two studies meeting its goal and a higher-than-expected placebo response, leading to investor disappointment.

via Investor's Business Daily|

#business #hidradenitis-suppurativa #moonlake

business5 months ago•2 min saved

Summit's Drug Trials Face Challenges and Mixed Results

Summit Therapeutics' stock plummeted nearly 17% after its experimental drug, ivonescimab, failed to improve overall survival in a lung cancer trial, casting doubt on its prospects for FDA approval and future partnerships.

via Investor's Business Daily|

#business #drug-failure #ivonescimab

business6 months ago•1 min saved

Viking Therapeutics Shares Plunge Amid Mixed Weight-Loss Pill Results

Viking Therapeutics' stock plummeted over 35% after mixed results from its weight-loss drug, which showed significant weight loss but also a high dropout rate due to side effects, leading to investor concern and a sharp decline in share price.

via Investor's Business Daily|

#business #glp-1 #mixed-results